The 7 Best Peptides for Longevity: An Evidence-Based Guide

The best longevity-peptide ranking is not the one with the boldest claims. It is the one that separates a plausible mechanism from evidence of benefit, accounts for regulatory status, and asks whether treatment can be monitored safely.

A 2026 narrative review of epitalon and epithalamin found that human evidence is largely limited to small physiological and biomarker studies. It concluded that adequately powered randomized trials have not established therapeutic efficacy for aging or longevity. Animal lifespan findings do not establish that a treatment extends human life.

Market growth is not proof of clinical benefit. A market analysis projected substantial expansion in the longevity-peptide market, but demand does not show that a therapy improves healthspan.

This guide ranks seven compounds by evidence architecture: regulatory status, clarity of mechanism, strength of human outcome data, and the availability of meaningful monitoring. Each entry connects what the therapy does with what evidence supports, the safety considerations, and the questions to raise with a clinician.

1. Sermorelin (GHRH Analog)

Sermorelin is a 29-amino-acid synthetic peptide matching the first 29 residues of human growth hormone-releasing hormone. It binds the GHRH receptor on anterior pituitary somatotrophs, a G protein-coupled receptor that activates adenylate cyclase and raises intracellular cyclic AMP, which triggers a pulse of the body's own growth hormone. Because the signal arrives upstream of the pituitary, somatostatin feedback still regulates output, so the therapy restores a rhythm rather than replacing a hormone.

What the Mechanism Promises and What the Data Shows

In an aging context, the rationale is that GH and IGF-1 secretion declines and that restoring pulsatility looks more physiological than injecting exogenous hormone. The gap is outcome data. No long-term trial shows that moving IGF-1 back toward a younger range changes disease incidence, functional capacity, or mortality. The original branded product was discontinued in the United States, so current use runs through compounding pharmacies under individualized prescribing.

The honest framing: sermorelin restores a signal. It doesn't reverse an outcome, and IGF-1 is a marker rather than a benefit.

Typical scenario: a 54-year-old man with low-normal IGF-1, decent sleep, and a strength-training habit asks whether nightly sermorelin will slow his decline. The defensible answer is that his numbers and his recovery may improve, and that neither is proof of extended healthspan.

• Baseline labs: IGF-1, fasting glucose, HbA1c, and lipids before the first dose, repeated to guide titration.
• Timing: nightly dosing spaced away from heavy meals, aligned with the natural nocturnal GH pulse.
• Stopping rules: predefined IGF-1 ceilings and glucose thresholds agreed before the first vial.

Peptide therapy works through receptor signaling rather than replacement, which an introductory guide to peptide therapy explains in more detail.

2. Tesamorelin

Tesamorelin is a 44-amino-acid GHRH analog with a trans-3-hexenoic acid modification. It acts at the GHRH receptor and stimulates pulsatile growth hormone release. Its established clinical role is narrower than a general longevity use: the FDA-approved indication is reduction of excess abdominal fat in adults with HIV-associated lipodystrophy, as described in the FDA prescribing information for tesamorelin.

Visceral Fat as the Measurable Endpoint

Visceral adipose tissue is linked to insulin resistance, dyslipidemia, and inflammatory signaling. A measurable reduction in this tissue is a more relevant endpoint than a change in scale weight, but it does not establish longer life or broad healthspan benefit.

An evidence audit of longevity and metabolic peptides reports improved executive function in one older-adult tesamorelin trial. It also describes improved walking distance in older adults using semaglutide, tirzepatide, or liraglutide, with gains generally associated with weight loss; strength outcomes were not consistently reported. These findings do not establish tesamorelin as a longevity treatment.

For a patient whose waist circumference and fasting insulin remain difficult to improve despite diet and resistance training, the clinician should define the treatment target before considering a drug. DXA or cross-sectional imaging can provide a baseline measure of visceral fat; a bathroom scale cannot distinguish visceral from other weight changes.

• Ask about measurement: establish whether visceral fat will be assessed before and during therapy, and how results will guide continuation.
• Review safety factors: glucose control, diabetes, and malignancy history should be addressed during intake.
• Set the treatment context: consider tesamorelin only in relation to a defined clinical goal, rather than assuming it is a stand-alone longevity intervention.

3. Ipamorelin

Ipamorelin is a pentapeptide that activates the growth hormone secretagogue receptor, also called the ghrelin receptor, on pituitary somatotrophs. It prompts growth hormone release. Compared with earlier secretagogues, it is described as having less effect on cortisol, prolactin, and appetite at typical doses. It is often paired with a GHRH analog: the combined signals can produce a larger GH pulse than either signal alone.

The Evidence Ceiling for Secretagogues

Ipamorelin's mechanism is clearer than its evidence for longevity. Animal and laboratory research can examine GH release, but it does not establish longer life or better healthspan in people. Human longevity outcomes are absent, and the evidence presented here does not establish a clinical benefit for ipamorelin.

Practical rule: before starting, ask how the prescriber will monitor IGF-1, fasting glucose, and symptoms, and how often results will be reviewed.

• Anti-doping: disclose any testing program, because GH secretagogues are restricted in many sport settings.
• Monitoring: agree on defined check-ins rather than open-ended use.
• Regulatory status: ipamorelin is not FDA-approved as a longevity therapy.

4. NAD+ (Nicotinamide Adenine Dinucleotide) Therapy

NAD+ isn't a peptide. It's a dinucleotide coenzyme in glycolysis, the citric acid cycle, and oxidative phosphorylation, and a substrate for sirtuins, PARPs, and CD38, the enzymes positioned in DNA repair, gene expression, and inflammatory signaling. Its place in a longevity list reflects that role in cellular energy and repair rather than any receptor mechanism.

What the Trials Actually Measured

Route matters. Oral precursors reach the bloodstream and raise NAD+ metabolites, while injections and infusions bypass the gut entirely. The endpoints are narrower than the marketing. A 2025 pilot reported in PubMed Central enrolled 8 participants with peripheral artery disease and found that 4 weeks of oral nicotinamide riboside increased peripheral endothelial-function measurements from 2.2% ± 3.6% to 9.0% ± 7.6%. A separate 24-week randomized trial of 58 people with long COVID, reported by Massachusetts General Hospital researchers, found no major between-group differences in its primary cognitive outcomes for nicotinamide riboside versus placebo.

Those two results tell the story in miniature: a small positive vascular signal and a clean null in cognition, from studies far too short to speak to lifespan.

• Route question: ask whether injection, infusion, or an oral precursor fits the goal, since the pharmacokinetics differ.
• Baseline function: metabolic and renal panels first, because tolerance varies between patients.
• Rate control: start infusions slowly and report flushing or discomfort immediately rather than pushing through it.

5. Glutathione

Glutathione is a tripeptide made from glutamate, cysteine, and glycine. Inside cells, it helps glutathione peroxidase and glutathione S-transferase manage reactive oxygen species and process certain compounds. Its role in antioxidant pathways makes it biologically relevant, but that mechanism alone does not establish a longevity benefit.

The Formulation Problem

Oral glutathione, injectable glutathione, and intravenous administration differ in how the compound is delivered. A 2025 industry analysis of parenteral peptide therapeutics described peptide instability and limited gastrointestinal bioavailability as factors shaping interest in parenteral formulations. Market demand, however, does not demonstrate clinical benefit.

Evidence that supplementation improves long-term health outcomes remains limited. FDA materials on injectable peptide safety describe concerns about immunogenicity, aggregation, and peptide-related impurities. A 2026 review in gerontology discusses unresolved questions about glutathione dosing, combination effects, and which biomarkers should be used to assess efficacy.

For a clinician, the decision rests on the intended indication, formulation quality, and a monitoring plan. Ask what outcome would justify continuing treatment, and what finding would prompt a stop.

• Disclose: asthma, sulfite sensitivity, and all current medications.
• Verify: ask how the preparation is sourced and what quality documentation is available.
• Measure: agree in advance on relevant markers and when the protocol will be reassessed.

6. MIC + B12 Lipotropic Injections

MIC + B12 combines methionine, inositol, and choline with methylcobalamin. Methionine supplies methyl groups through S-adenosylmethionine and supports hepatic methylation reactions. Choline is a precursor for phosphatidylcholine, which is required for very-low-density lipoprotein export and fat transport out of the liver. Inositol acts as a component of second messengers in insulin signaling, and methylcobalamin is a cofactor for methionine synthase, tying B12 status to methylation and homocysteine metabolism.

Where the Evidence Sits

B12 replacement for documented deficiency is well established. The claim that the lipotropic combination drives fat loss is not, and injections work best as an adjunct to a structured nutrition and activity plan rather than a stand-alone intervention. The markers that make the protocol legible are baseline B12, homocysteine, and a metabolic panel, followed by reassessment on a schedule.

Scenario: a patient on an incretin protocol who reports fatigue at week eight. Here the injection functions as a targeted correction guided by a B12 and homocysteine result, not as a generic energy boost.

Before you start: ask how the lipotropic protocol fits with any incretin therapy already in progress, so the provider can sequence the two rather than stack them blindly.

For anyone weighing this alongside broader metabolic work, the practical order is labs first, then nutrition and resistance training, then adjuncts. A guide to improving metabolic health covers the foundation that injections can't replace.

7. Semaglutide and Tirzepatide as Metabolic Healthspan Therapies

Semaglutide is a GLP-1 receptor agonist, and tirzepatide adds GIP receptor agonism on top. Both enhance glucose-dependent insulin secretion, suppress glucagon, slow gastric emptying, and act on hypothalamic appetite regulation. Their longevity relevance is indirect but well measured: they change insulin sensitivity, body weight, blood pressure, and lipid profiles, which are the cardiometabolic risk factors that predict disease.

The Strongest Human Data in This List

The SELECT trial randomized more than 17,000 adults with overweight or obesity and established cardiovascular disease, and semaglutide reduced major cardiovascular events by 20%, as summarized in a review of peptide evidence across GLP-1 and longevity categories. That's a disease outcome rather than a biomarker, and it still doesn't establish slower biological aging in healthy adults.

Weight data are equally concrete. In the FDA review of tirzepatide for chronic weight management, a 72-week randomized, double-blind trial produced an average reduction of approximately 18% of baseline body weight at the 15 mg weekly dose in participants without diabetes, and approximately 12% in a parallel trial of adults with type 2 diabetes, across 2,519 tirzepatide-treated and 958 placebo-treated participants.

For semaglutide, FDA prescribing information covering 68-week studies reports that 83.5% of treated participants reached at least 5% weight loss versus 31.1% on placebo, 67.4% reached at least 10% versus 30.2%, and 20.8% reached at least 15% versus 2.6%, a placebo-adjusted mean difference of about 12.4 percentage points.

• Intake: thyroid cancer history, pancreatitis history, and a complete medication list before any prescription.
• Lean mass: protein targets, resistance training, and a sodium and fluid plan to protect muscle.
• Titration: gradual, provider-directed escalation, with the safety profile of semaglutide reviewed before the first dose.

Longevity Peptides at a Glance

The practical differences are route, evidence limits, and what a clinician can monitor. These determine how much uncertainty a protocol carries; a mechanism alone does not establish a longevity benefit.

This is an evidence-and-monitoring comparison, not a ranking of longevity effects. For NAD+ therapy, the concrete human finding is increased NAD+ metabolites; whether that translates into better healthspan remains uncertain. A clinician should match the monitoring plan to the intended indication, rather than treating a biomarker change as proof of benefit.

Matching the Molecule to Your Biology, Next Steps

Continuation is part of the treatment decision. In the FDA-reviewed tirzepatide prescribing information, participants who stopped therapy after prior treatment had less favorable weight trajectories than those who continued. For eligible patients, that finding makes it important to discuss the likely duration of treatment and a plan for ongoing clinical review before starting.

A clinician-led protocol should connect the proposed therapy to a specific indication, baseline assessment, monitoring plan, and criteria for pausing or stopping. Licensed providers determine eligibility and prescribing decisions after reviewing an individual's intake. Compounded medications are prescribed only at their clinical discretion, and neither a prescription nor an outcome is promised.

Vials + Vitals lists NAD+ Nasal Spray, NAD+ 1000 mg Injection, Sermorelin, Glutathione, and MIC B12 in its peptide and wellness therapy area. Start with the confidential online intake at Vials + Vitals to explore whether an available option may fit your clinical needs.

Informational purposes only. A licensed provider evaluates individual suitability, and prescriptions are fulfilled by state-licensed partner compounding pharmacies.